TABLE 2.
Sensitivity, specificity, PPV, and NPV with 95% CIs for diagnoses of CIN2+ and CIN3 for hrHPV detection by cobas HPV and AHPV testsa
| Value type by CIN grade | AHPV |
Cobas |
P | ||
|---|---|---|---|---|---|
| Value (%) | 95% CI (%) | Value (%) | 95% CI (%) | ||
| CIN2+b | |||||
| Sensitivity | 89.4 | 81.3–94.8 | 89.4 | 81.3–94.8 | 1 |
| Specificity | 63.1 | 59.8–66.3 | 59.3 | 56.0–62.5 | 0.0003 |
| PPV | 20.3 | 16.5–24.5 | 18.8 | 15.2–22.7 | 0.01 |
| NPV | 98.30 | 96.80–99.20 | 98.10 | 96.60–99.10 | 0.8 |
| CIN3+b | |||||
| Sensitivity | 95.2 | 83.8–99.4 | 92.9 | 80.5–98.5 | 1 |
| Specificity | 60.5 | 57.3–63.6 | 56.8 | 53.5–59.9 | 0.0002 |
| PPV | 9.7 | 7.0–12.9 | 8.7 | 6.3–11.7 | 0.03 |
| NPV | 99.70 | 98.70–100 | 99.40 | 98.40–99.90 | 0.5 |
a
PPV, positive predictive value; NPV, negative predictive value; CIN2+, cervical intraepithelial grade 2 or more; CIN3, cervical intraepithelial grade 3; hrHPV, high-risk human papillomavirus; AHPV, Aptima HPV. Differences in sensitivity and specificity were tested for statistical significance using an exact version of the McNemar chi-square test.
b
Includes one case of adenocarcinoma in situ.